康芝药业(300086) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥118,694,152.72, a decrease of 1.12% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2023 was -¥36,763,835.68, a decline of 68.34% year-on-year[4] - Year-to-date revenue increased by 29.37% to ¥451,718,553.98 compared to the same period last year[4] - Year-to-date net profit attributable to shareholders increased by 81.34% to -¥20,452,467.40 compared to the same period last year[4] - The basic earnings per share for Q3 2023 was -¥0.0817, a decrease of 68.45% year-on-year[4] - The diluted earnings per share for Q3 2023 was also -¥0.0817, reflecting the same decline of 68.45% year-on-year[4] - Total operating revenue for Q3 2023 reached CNY 451,718,553.98, an increase of 29.5% compared to CNY 349,165,788.89 in the same period last year[16] - Total operating costs amounted to CNY 480,764,567.55, up from CNY 468,685,760.75, reflecting a year-over-year increase of 2.3%[16] - Net loss for the period was CNY 23,132,111.59, compared to a net loss of CNY 112,493,434.00 in the previous year, indicating a significant reduction in losses[18] - Basic and diluted earnings per share were both reported at -0.0454, compared to -0.2436 in the previous year, showing improvement in per-share performance despite ongoing losses[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,087,662,073.63, down 8.77% from the end of the previous year[4] - The total assets decreased from CNY 2,288,471,761.40 to CNY 2,087,662,073.63, a decline of approximately 8.8%[15] - Total liabilities decreased from CNY 932,963,148.62 to CNY 746,339,922.43, a reduction of about 20%[15] - The company's equity attributable to shareholders decreased from CNY 1,316,183,105.82 to CNY 1,304,496,288.43, a slight decline of 0.9%[15] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥17,931,054.11, a significant decrease of 520.72% year-on-year[4] - Operating cash inflow totaled ¥492,490,503.81, a decrease of 6.8% from ¥528,229,417.87 in the previous period[22] - Net cash flow from operating activities was -¥17,931,054.11, compared to -¥2,888,761.92 in the previous period, indicating a worsening cash flow situation[22] - Cash outflow from investing activities was ¥41,887,330.99, up from ¥33,300,742.18 in the previous period, leading to a net cash flow from investing activities of -¥38,308,530.99[22] - Cash inflow from financing activities was ¥62,733,890.33, significantly lower than ¥154,312,620.20 in the previous period, resulting in a net cash flow from financing activities of -¥108,929,819.31[22] - The ending balance of cash and cash equivalents was ¥93,319,047.36, down from ¥178,569,049.04 in the previous period[22] - The company received cash from sales of goods and services amounting to ¥433,597,129.16, a decrease from ¥449,701,155.00 in the previous period[22] - Cash received from tax refunds was ¥28,295,272.75, an increase from ¥24,321,061.01 in the previous period[22] - Cash paid for operating activities totaled ¥510,421,557.92, slightly down from ¥531,118,179.79 in the previous period[22] - Cash paid to employees was ¥78,670,556.71, an increase from ¥74,025,064.45 in the previous period[22] Operational Highlights - The company reported non-operating income of ¥1,103,436.86 for the current period, with government subsidies contributing significantly[5] - The company received the "Hebei Province Worker Pioneer" honor for its subsidiary, Hebei Kangzhi Pharmaceutical Co., Ltd.[11] - The company showcased its star anti-allergy product, Levocetirizine Hydrochloride Granules, at the 11th Jiangsu-Zhejiang-Shanghai-Anhui Pediatric Respiratory Forum[12] - Kangzhi Pharmaceutical provided financial assistance to 100 economically disadvantaged disabled girls in Chaozhou through its charity fund[12] Inventory and Current Assets - As of September 30, 2023, the total current assets of Kangzhi Pharmaceutical amounted to CNY 525,767,629.86, a decrease from CNY 670,460,025.37 at the beginning of the year, representing a decline of approximately 21.6%[13] - The cash and cash equivalents decreased significantly from CNY 269,812,342.27 to CNY 104,642,937.86, indicating a reduction of about 61.2%[13] - Inventory levels increased from CNY 170,403,668.09 to CNY 264,127,007.92, reflecting a growth of approximately 55%[13] - Accounts receivable decreased from CNY 71,130,846.60 to CNY 45,663,739.11, a decline of about 35.8%[13] - The company’s long-term investments remained stable at CNY 5,946,251.81[13] - Fixed assets decreased from CNY 890,943,057.14 to CNY 856,787,759.89, a reduction of approximately 3.8%[13] - The company’s total non-current assets remained unchanged at CNY 237,607,487.29 for investment properties[13] Research and Development - Research and development expenses increased to CNY 14,297,192.84, up from CNY 11,781,021.35, representing a growth of 21.5% year-over-year[16] Financial Reporting - The third quarter report was not audited, indicating potential risks in financial reporting accuracy[24]